热门资讯> 正文

免疫工程GAAP每股收益为-0.27美元在线

2026-08-05 19:43

Immuneering(IMRX) 0

Immuneering press release (IMRX): Q2 GAAP EPS of -$0.27 in-line.
Ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029

More on Immuneering

Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
Immuneering Corporation: Updates Inbound At The End Of The Month
Seeking Alpha’s Quant Rating on Immuneering
Historical earnings data for Immuneering

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。